Comparing Two Interferon Treatments for Melanoma
Author Information
Author(s): Chiarion-Sileni Vanna, Del Bianco Paola, Romanini Antonella, Guida Michele, Paccagnella Adriano, Dalla Palma Maurizio, Naglieri Emanuele, Ridolfi Ruggero, Silvestri Barbara, Michiara Maria, De Salvo Gian Luca
Primary Institution: Department of Medical Oncology, University Hospital, Padua, Italy
Hypothesis
Can a more intense but shorter interferon treatment improve survival for stage III melanoma patients without increasing toxicity?
Conclusion
The study found that four cycles of intravenous high-dose interferon can be safely delivered with an increase in the median dose intensity.
Supporting Evidence
- The most common toxicities were flu-like and gastrointestinal symptoms.
- Leukopenia was more frequent in the DD/DI arm than in the HDI arm (24% vs 9%).
- The median actual dose intensity delivered in the DD/DI arm was significantly higher than that in the HDI arm.
Takeaway
Doctors wanted to see if giving a stronger dose of medicine for a shorter time would help people with skin cancer without making them feel worse. It looks like it worked better than the usual way.
Methodology
Patients were randomized to receive either a more intense intravenous interferon treatment or a standard treatment, and toxicity was recorded and graded.
Limitations
The study only reports on the first 169 patients and does not provide long-term efficacy results.
Participant Demographics
101 males and 65 females, mean age 49.1 years.
Statistical Information
P-Value
0.0074
Confidence Interval
95% confidence interval: 7.3–8.9
Statistical Significance
p = 0.0074
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website